Euglena (TSE:2931) Stock Price Slides Even As Profit Returns

Euglena stock closed at ¥340 on 7 August, capping a 90 day slide of about 15%. Yet the latest quarter flipped the script where it matters most. Q2 2026 delivered a return to profit with basic earnings per share of ¥0.75 on revenue of ¥13,310m. That shift from prior losses is the headline. The near term chart still looks bruised. The multi year story now hinges on whether this profit spark can sustain and support the valuation case built on shrinking losses and upbeat earnings forecasts.

Love the return to profit at Euglena but concerned that one quarter might not be enough to support your thesis? Compare this setup with other turnaround stories in our 63 high quality undiscovered gems

Q2 2026 Earnings Summary

• Revenue (Q2 2026 vs Q2 2025): ¥13,310m vs. ¥12,618m (single digit percentage growth year on year)
• Net Income, Excluding Extraordinary Items (Q2 2026 vs Q2 2025): profit of ¥105m vs. loss of ¥52m (swing back into profit)
• Basic EPS (Earnings Per Share) (Q2 2026 vs Q2 2025): ¥0.75 vs. a loss of ¥0.38 per share (return to positive EPS)
• Trailing Twelve Month Net Income, Excluding Extraordinary Items (TTM to Q2 2026 vs TTM to Q2 2025): loss of ¥173m vs. loss of ¥942m (material narrowing of full year losses)

Prefer clean charts over scrolling through pages of raw earnings figures and balance sheet line items? See Euglena’s full financial picture, including an at a glance view of its recent profitability shift, in our company report for Euglena.

Euglena’s profit return gives bulls something real

Euglena finally put numbers behind the green innovation story. Revenue reached ¥13,310m and the company moved from a loss to a profit of ¥105m, with basic EPS at ¥0.75. Trailing twelve month losses narrowed to ¥173m from ¥942m. For a business often framed as long term and project heavy, this shift toward breakeven supports the idea that core health foods and related activities can shoulder more of the financial load.

Recent losses still keep the cautious view alive

The latest quarter looks better, but the share price at ¥340 after a 90 day decline of about 15% shows investors are still cautious. Euglena is profitable this quarter yet the trailing twelve month result remains a ¥173m loss. That fits a story where biofuel and broader research projects still weigh on the bottom line. One profitable quarter helps. It does not fully address concerns about the consistency of earnings or the cash demands of multiple business lines.

Compare Euglena’s move back into profit with the share price slide and consider whether the street views this as the start of a real turnaround or just a temporary blip. Highlight the gap between the story in the accounts and institutional expectations with the consensus price target analysis for Euglena.

Stay Ahead With Simply Wall St

If Euglena’s swing back to profit has your attention but the recent share price slide keeps you cautious, register for free with Simply Wall St and add it to a Watchlist to track price against fair value and watch how the thesis develops. When you decide to take a position, use the Portfolio Command Center to cut through noise and focus on the most important updates for your holdings. For longer term conviction, tap into crowd insights and sentiment through the Community so you can see how other investors are interpreting new data points. By surfacing potential catalysts and risks early across your stocks, Simply Wall St helps you stay a step ahead of the market.

Seeking Alternatives Beyond Euglena?

Fresh ideas move first when momentum starts building. Do not get caught chasing stocks already flying. Scan these focused shortlists while it matters and get in early.

• Spot steady compounders with robust cash flows and conservative leverage by reviewing the curated list of solid balance sheet and fundamentals stocks (40 results) before the crowd notices the balance sheet strength.
• Identify income-focused opportunities as yields react to shifting sentiment by scanning the hand picked 43 dividend fortresses while payouts and coverage ratios are still under the radar for now.
• Track early movers in critical materials by checking the focused 28 best rare earth metal stocks before momentum traders start bidding up potential future supply chain winners.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com